Does a Series B biotech company need a fractional Chief Revenue Officer in 2027?

Direct Answer

A Series B biotech company in 2027 often faces a specific inflection point: you have a validated therapeutic or diagnostic platform, some initial revenue from partnerships or early sales, but you lack the structured revenue operations, sales process, and leadership to scale predictably. A fractional CRO fills this gap without the long-term commitment and high cash compensation of a full-time executive (typically $250,000–$400,000 base plus equity). You get experienced leadership that can build a GTM playbook, hire the first sales team, and align your commercial strategy with your clinical milestones—while you retain the flexibility to pivot or go full-time later. The decision hinges on your revenue maturity, cash runway, and whether you need a builder or a manager.

When a fractional CRO makes sense for a Series B biotech

At Series B, your company likely has a product in development or early commercialization, a small commercial team (or none), and a board expecting a clear path to revenue. The founder often still owns sales, but clinical and regulatory demands are pulling them away. A fractional CRO can step in to build the commercial function from scratch—defining target accounts, setting pricing, creating a sales process, and hiring the first sales or business development hires.

The honest truth: most biotech founders at this stage overestimate their ability to sell while running R&D. You might close a few deals on relationships, but you lack a repeatable system. A fractional CRO brings a playbook from other life science companies, avoiding costly mistakes like hiring the wrong salesperson or chasing the wrong market segment.

Fractional vs full-time CRO: the real trade-offs

> Callout: A fractional CRO is not a "cheap CRO." You pay for their experience, not their time. If you need daily operational management of a 10-person sales team, you likely need a full-time VP of Sales, not a fractional CRO.

What a fractional CRO actually does in a Series B biotech

The work is not just "making calls." A good fractional CRO in a biotech context will:

• Audit your current GTM – Review existing partnerships, pipeline, pricing, and competitive positioning. Deliver a 30-day assessment with specific gaps and recommendations.
• Define your ideal customer profile (ICP) – Biotech often has multiple buyer personas: pharma partners, hospital systems, CROs, or distributors. The fractional CRO will help you prioritize.
• Build a sales process – Create stages from lead generation to close, with clear milestones and qualification criteria. This is often missing in early-stage biotechs.
• Hire and train the first commercial team – Write job descriptions, interview candidates, and onboard the first 2–5 sales or BD people. They will also define compensation plans and quotas.
• Establish revenue operations – Set up CRM (Salesforce or HubSpot), define pipeline reporting, and create dashboards for board meetings. Many biotechs have no CRM at all.
• Lead key negotiations – A fractional CRO can personally manage the largest partnership or licensing deal, leveraging their network and experience.

> Callout: If your biotech is pre-revenue and 18+ months from any commercial activity, a fractional CRO is likely premature. You need a fractional commercial advisor or BD consultant at a lower cost ($3k–$8k/month) to prepare for future commercialization.

The cost structure: honest ranges

Fractional CRO pricing in biotech varies widely. Here are the real drivers:

• Days per month – 10 days ($8k–$12k), 15 days ($12k–$16k), 20 days ($16k–$20k+). Some charge a flat monthly retainer, others a day rate ($800–$1,500/day).
• Equity component – Many fractional CROs will accept a lower cash rate in exchange for equity (0.5–1.5% vesting over 2–3 years). This aligns incentives but dilutes founders.
• Scope complexity – If you need them to also manage a small sales team, run board presentations, and negotiate partnerships, expect the higher end of the range.
• Geographic premium – Boston and San Francisco-based fractional CROs charge more than those in lower-cost regions, but remote work has narrowed this gap. You can hire a strong fractional CRO from anywhere if they have biotech experience.

No single invented figure here – the right cost for you depends on the above variables. Get 3–4 proposals and compare scope, not just price.

How to find and vet a fractional CRO for biotech

The market for fractional CROs is fragmented. Here is a practical search process:

1. Tap your network – Ask your board members, investors, or fellow biotech founders for referrals. Pavilion (joinpavilion.com) and RevOps Co-op are good communities to post a request.
2. Interview for biotech-specific knowledge – Ask them: "How do you handle a sales cycle that involves FDA feedback?" or "How do you price a platform technology versus a single product?" If they cannot answer with specifics, move on.
3. Check references – Talk to 2–3 previous clients, ideally in biotech or medtech. Ask: "What did they build that lasted after they left?" and "What was the biggest mistake they helped you avoid?"
4. Start with a paid pilot – Offer a 30-day paid engagement ($3k–$5k) for a GTM audit before committing to a longer contract. This tests fit with minimal risk.

When to say no to a fractional CRO

A fractional CRO is not always the answer. Avoid them if:

• Your company is pre-revenue and more than 18 months from any commercial launch – You need a commercial strategist, not a revenue leader.
• You already have a strong VP of Sales or BD who just needs coaching – A fractional CRO may create confusion about who owns revenue.
• Your board expects a full-time executive – Some investors view fractional leadership as a sign of instability. Check alignment before hiring.
• You are unwilling to give them decision-making authority – A fractional CRO needs autonomy to hire, fire, and set strategy. If you micromanage, you waste their expertise and your money.

FAQ

What is the typical engagement length for a fractional CRO in biotech? Most engagements run 6–12 months. Some extend to 18 months if the company is still early in commercialization. A 3-month minimum is standard.

Can a fractional CRO work effectively if they are not on-site? Yes, if the company has a strong ops backbone (CRM, Slack, weekly standups). Biotech clusters (Boston, SF, San Diego) allow for monthly on-site visits. Remote-only works for companies with a remote-first culture.

Do fractional CROs take equity? Many do, especially if the cash budget is tight. Typical equity ranges from 0.5% to 1.5% vesting over 2–3 years with a 1-year cliff. This aligns long-term incentives but dilutes founders.

How do I transition from fractional to full-time CRO? Set a 6-month review with clear milestones (pipeline value, hires made, revenue closed). If the fractional CRO has delivered and you need them full-time, negotiate a conversion—often with a reduced cash salary and a larger equity grant.

What if my biotech is in a niche like gene therapy or diagnostics? Look for a fractional CRO with specific experience in that sub-sector. General biotech experience is better than none, but niche knowledge reduces ramp-up time and increases credibility with partners.

Will a fractional CRO attend board meetings? Usually yes, for the portion covering commercial strategy. This is often included in the retainer or billed as an extra day per month. Clarify this upfront.

Sources

• Pavilion – Community for revenue leaders
• RevOps Co-op – Revenue operations community
• Harvard Business Review – Sales and marketing strategy
• First Round Review – Startup leadership and hiring
• SaaStr – SaaS and revenue leadership insights
• LinkedIn – Network for fractional CRO candidates

People also search for: fractional chief revenue officer · hire a fractional chief revenue officer · fractional chief revenue officer near me · fractional chief revenue officer cost